4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Bank of America Co. from $42.00 to $40.00. They now have a "buy" rating on the stock.